YPX-C-05

CAS No. 2894823-79-9

YPX-C-05( —— )

Catalog No. M37338 CAS No. 2894823-79-9

YPX-C-05 is an isohydroxamic acid derivative and HDAC inhibitor with vasodilatory and antihypertensive activity.YPX-C-05 is used in the study of hypertension and vascular related disorders.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 459 In Stock
10MG 657 In Stock
25MG 1026 In Stock
50MG 1386 In Stock
100MG 1832 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    YPX-C-05
  • Note
    Research use only, not for human use.
  • Brief Description
    YPX-C-05 is an isohydroxamic acid derivative and HDAC inhibitor with vasodilatory and antihypertensive activity.YPX-C-05 is used in the study of hypertension and vascular related disorders.
  • Description
    YPX-C-05 is a hydroxamic acid-based HDAC inhibitor. YPX-C-05 exerts significant vasodilatory effects. YPX-C-05 exhibits inhibitory effects on HDACs and increases histone H4 acetylation in endothelial cells. YPX-C-05 can be used for hypertension research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2894823-79-9
  • Formula Weight
    377.39
  • Molecular Formula
    C21H19N3O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NC=1C=CC(=CC1)C2=CC=CC(OC)=C2)NC3=CC=C(C=C3)C(=O)NO
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Pang PP, et al. The hydroxamic acid derivative YPX-C-05 alleviates hypertension and vascular dysfunction through the PI3K/Akt/eNOS pathway. Vascul Pharmacol. 2023 Dec 3;154:107251. ?
molnova catalog
related products
  • MPT0B390

    MPT0B390 is an inhibitor of HDAC and a TIMP3 inducer inhibiting tumor growth, metastasis, and angiogenesis.

  • HDACi-4b

    A benzamide-type HDAC inhibitor with IC50 of 78 uM for changes of FXN mRNA in affected GM15850 cells.

  • Tasquinimod

    An orally active antiangiogenic agent with anti-prostate cancer activity, an allosteric modulator of HDAC4 with Kd of 10-30 nM.